Adverse Events of Pirfenidone for the Treatment of Pulmonary Fibrosis: A Meta-Analysis of Randomized Controlled Trials

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Jiang, Chunguo ^a   Huang, Hui ^a   Liu, Jia ^a   Wang, Yanxun ^a   Lu, Zhiwei ^b   Xu, Zuojun ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b WANNAN MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; PLACEBO;

ANOREXIA; ANXIETY DISORDER; ARTICLE; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; INSOMNIA; LUNG FIBROSIS; META ANALYSIS; NAUSEA; NEUROTOXICITY; PHOTOSENSITIVITY; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN TOXICITY; SYSTEMATIC REVIEW; VOMITING;

HUMANS; PULMONARY FIBROSIS; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84867320020     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047024     Document Type: Article

References (22)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, et al. (2011) An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med 183: 788-824.
2. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G, (2006) Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174: 810-816.
3. King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, et al. (2009) Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 374: 222-228.
4. King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, et al. (2011) BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184: 92-99.
5. Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, et al. (2008) Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 178: 948-955.
6. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, et al. (2010) Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenaf il in advanced idiopathic pulmonary fibrosis. N Engl J Med 363: 620-628.
7. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, et al. (2005) IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353: 2229-2242.
8. Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, et al. (1995) Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 125: 779-785.
9. Schelegle ES, Mansoor JK, Giri S, (1997) Pirfenidone attenuates bleomycin-induced changes in pulmonary functions in hamsters. Proc Soc Exp Biol Med 216: 392-397.
10. Giri SN, Leonard S, Shi X, Margolin SB, Vallyathan V, (1999) Effects of pirfenidone on the generation of reactive oxygen species in vitro. J Environ Pathol Toxicol Oncol 18: 169-177.
11. Raghu G, Johnson WC, Lockhart D, Mageto Y, (1999) Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 159(4 Pt 1): 1061-1069.
12. Gahl WA, Brantly M, Troendle J, Avila NA, Padua A, et al. (2002) Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab 76: 234-242.
13. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, et al. (2005) Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171: 1040-1047.
14. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, et al. (2010) Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35: 821-829.
15. O'Brien K, Troendle J, Gochuico BR, Markello TC, Salas J, et al. (2011) Pirfenidone for the treatment of Hermansky-Pudlak syndrome pulmonary fibrosis. Mol Genet Metab 103: 128-134.
16. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, et al. (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377: 1760-1769.
17. Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, et al. (2010) Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 9: CD003134.
18. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials 17: 1-12.
19. Costabel U, Albera C, Cohen A, Bradford W, King TE Jr, et al. (2011) The long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Interim data from the RECAP extension study. Proceedings of European Respiratory Society Annual Congress. Amsterdam, September 24-28.
20. Shi S, Wu J, Chen H, Chen H, Wu J, et al. (2007) Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol 47: 1268-1276.
21. Rubino CM, Bhavnani SM, Ambrose PG, Forrest A, Loutit JS, (2009) Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 22: 279-285.
22. Baba T, Ogura T, Kato T, Shiihara J, Matsushima A, et al. (2009) Safety Analysis of Pirfenidone in Clinical Use. Respirology 14 (Suppl. 3): A156.